ImmunoGen Inc. About
ImmunoGen Inc. ImmunoGen, Inc. develops targeted anticancer therapeutics.
ImmunoGen's TAP technology uses tumor-targeting antibodies to deliver a
potent cell-killing agent specifically to cancer cells. Antibodies
with or without anticancer activity can become potent cancer-killing agents with
TAP technology.
HuN901-DM1, developed
by ImmunoGen -- treatment of cancers that express the antigen CD56. These include
small-cell lung cancer (SCLC), other cancers of neuroendocrine origin,
and certain hematologic malignancies. MLN2704, developed by
Millennium Pharmaceuticals --targets the prostate-specific membrane antigen
(PSMA) Cantuzumab mertansine, has completed Phase I testing
--cancers that express the CanAg antigen. These include colorectal, pancreatic,
and other gastrointestinal cancers, as well as many non-small-cell lung
More
on Immunogen Key
Statistics for Immunogen
Basic
Chart for Immunogen